CDP-870. Celltech/Pfizer.
Celltech Group plc (formerly Celltech Chiroscience), in collaboration with Pfizer Inc (formerly Pharmacia Corp), is developing CDP-870, a polyethylene glycol (PEG)ylated anti-TNF antibody fragment, for the potential treatment of certain autoimmune and inflammatory diseases, including rheumatoid arthritis (RA) and Crohn's disease (CD). In October 2002, Pharmacia initiated phase III trials for RA and at this time Celltech anticipated initiating phase III trials for CD in mid-2003.
Rose-John
Stefan
S
Department of Biochemistry, Christian-Albrechts-Universität zu Kiel, 40 Olshausenstrasse, D-24098 Kiel, Germany. rosejohn@biochem.uni-kiel.de
Schooltink
Heidi
H
D000818:Animals; D061067:Antibodies, Monoclonal, Humanized; D001327:Autoimmune Diseases / Q000188:drug therapy; D000068582:Certolizumab Pegol; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D006801:Humans; D007140:Immunoglobulin Fab Fragments; D011092:Polyethylene Glycols / Q000494:pharmacology / Q000627:therapeutic use*; D013678:Technology, Pharmaceutical / Q000331:legislation & jurisprudence / Q000379:methods*
D061067:Antibodies, Monoclonal, Humanized; D007140:Immunoglobulin Fab Fragments; D011092:Polyethylene Glycols; D000068582:Certolizumab Pegol